Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersonGen CD22 CAR-T in Relapsed/Refractory B-Cell Malignancies
NCT03999697Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD22 chimeric antigen receptor T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and 3 more, sponsored by PersonGen BioTherapeutics. Primary endpoints: Adverse Events That Are Related to Treatment at 2 years and The effect after treatment at 24 weeks. Status: unknown.
02
Drugs
anti-CD22 chimeric antigen receptor T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03999697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999697.